Karyopharm Therapeutics | KPTI - Ebitda


Karyopharm Therapeutics reported $-26.2M in EBITDA for its fiscal quarter ending in September of 2024.





Ebitda Change Date
AbbVie USD 5.37B 1.85B Dec/2025
Abbott USD 2.43B 844M Mar/2026
Amgen USD 5.14B 775M Dec/2025
AstraZeneca USD 5.67B 1.29B Mar/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Eli Lilly USD 12.14B 4.26B Dec/2025
GlaxoSmithKline GBP 2.77B 1.65B Mar/2026
Incyte USD 367.97M 46.53M Mar/2026
J&J USD 8.27B 1.08B Mar/2026
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
MacroGenics USD -30.2M 52.15M Mar/2026
Merck USD 6.3B 2.09B Dec/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Novartis USD 6.48B 1.19B Jun/2026
Novartis USD 5.41B 431M Mar/2026
Pfizer USD 5.99B 5.23B Mar/2026
Regeneron Pharmaceuticals USD 1.2B 718.4M Dec/2025
Roche Holding CHF 13.43B 744M Jun/2026
Takeda JPY 150.25B 297.88B Mar/2026
Tectonic Therapeutic USD -21.18M 365K Dec/2025
TG Therapeutics USD 51.69M 19M Dec/2025
Ultragenyx Pharmaceutical USD -99.43M 57.35M Dec/2025
Xencor USD -51.05M 55.28M Dec/2025